We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-3.5%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.82B
AUM Growth
-$609M
Cap. Flow
-$347M
Cap. Flow %
-19.1%
Top 10 Hldgs %
52.59%
Holding
435
New
56
Increased
93
Reduced
114
Closed
122

Top Buys

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$9.22M
2
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$7.3M
3
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$7.22M
4
UTHR icon
United Therapeutics
UTHR
+$5.06M
5
LUMO
Lumos Pharma, Inc. Common Stock
LUMO
+$4.98M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$22.6M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$18.2M
3
VTRS icon
Viatris
VTRS
+$18.1M
4
PXD
Pioneer Natural Resource Co.
PXD
+$15M
5
EW icon
Edwards Lifesciences
EW
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 10.47%
2 Technology 0.45%
3 Consumer Staples 0.1%
4 Industrials 0.09%
5 Materials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AXN
401
DELISTED
Aoxing Pharmaceutical Company Inc.
AXN
– –
-2,134,054
Closed -$3.16M
OPXAW
402
DELISTED
Opexa Therapeutics, Inc.
OPXAW
– –
-382,765
Closed -$46K
MACK
403
CALL
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
– –
-64
Closed -$426K
CBPO
404
DELISTED
China Biologic Products Holdings, Inc.
CBPO
– –
-20,000
Closed -$1.8M
FNCX
405
DELISTED
Function(x) Inc.
FNCX
– –
-40,634
Closed -$666K
ZLTQ
406
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
– –
-10,000
Closed -$316K
IOC
407
DELISTED
Interoil Corporation
IOC
– –
-328,705
Closed -$11.1M
IOC
408
PUT
DELISTED
Interoil Corporation
IOC
– –
-3,356
Closed -$11.3M
ARIA
409
DELISTED
Ariad Pharmaceuticals Inc
ARIA
– –
-169,000
Closed -$987K
ARIA
410
PUT
DELISTED
Ariad Pharmaceuticals Inc
ARIA
– –
-1,690
Closed -$987K
SGYPW
411
PUT
DELISTED
Synergy Pharmaceuticals, Inc. - Warrants
SGYPW
– –
-1,613
Closed -$855K
FEIC
412
CALL
DELISTED
FEI COMPANY
FEIC
– –
-340
Closed -$2.48M
RLYP
413
DELISTED
RELYPSA INC COM
RLYP
– –
-69,980
Closed -$1.51M
DYAX
414
DELISTED
DYAX CORPORATION
DYAX
– –
-79,613
Closed -$1.52M
DYAX
415
PUT
DELISTED
DYAX CORPORATION
DYAX
– –
-1,017
Closed -$1.94M
SKBI
416
DELISTED
SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV)
SKBI
– –
-147,926
Closed -$141K
ZSPH
417
CALL
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
– –
-297
Closed -$1.95M
ZSPH
418
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
– –
-11,875
Closed -$780K
ZSPH
419
PUT
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
– –
-640
Closed -$4.2M
CYTR
420
DELISTED
CytRx Corp
CYTR
– –
-26,597
Closed -$456K
IMDZ
421
DELISTED
Immune Design Corp.
IMDZ
– –
-20,000
Closed -$244K
NDRM
422
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
– –
-12,416
Closed -$242K
RPTP
423
PUT
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
– –
-436
Closed -$264K
RPRX
424
PUT
DELISTED
Repros Therapeutics Inc.
RPRX
– –
-2,793
Closed -$2.08M
ETRM
425
DELISTED
EnteroMedics Inc.
ETRM
– –
-1,965
Closed -$536K
13 14 15 16
17

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2015 Portfolio in Review

As of Q4 2015, Sabby Management held 435 positions worth $1.82B, down 25% from $2.43B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Sabby Management withdrew a net $347M in Q4 2015, closing 122 positions and reducing 114 holdings. Its most notable exit was Biogen, an estimated $22.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 10% of assets, down from 13% a quarter earlier, followed by Technology and Consumer Staples.

Against the trend, Sabby Management opened a new position in Alkermes worth $10.5M.

  • Sabby Management's largest Q4 2015 buy was Alkermes: 131,671 shares worth $10.5M.
  • Sabby Management added most to Tobira Therapeutics, Inc. Common Stock in Q4 2015, an estimated $7.3M increase.
  • Sabby Management's biggest Q4 2015 reduction was Edwards Lifesciences, cutting an estimated $11.6M.
  • Sabby Management fully exited Biogen in Q4 2015, selling an estimated $22.6M.
  • Sabby Management's ten largest holdings make up 53% of its $1.82B portfolio in Q4 2015.
  • Sabby Management opened 56 new positions and closed 122 in Q4 2015.
  • Sabby Management's portfolio value fell 25% quarter-over-quarter to $1.82B.

Based on Sabby Management's 13F filing for Q4 2015, filed 16 Feb 2016.